Treats attention deficit hyperactivity disorder (ADHD). ANDA 205327, held by Osmotica Pharmaceuticals US. Methylphenidate Hydrochloride.
As of Nov 21, 2026, ANDA 205327 (Methylphenidate Hydrochloride), held by Osmotica Pharmaceuticals US, was first approved by FDA on Jul 28, 2017, with 3 approved supplements and 0 published complete response letters.
Methylphenidate hydrochloride extended-release tablets are indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 6 to 65 years old. Limitations of Use The use of methylphenidate hydrochloride extended-release tablets is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 28, 2017 | Original application | Approved |
| Methylphenidate Hydrochloride18MG · tablet, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride27MG · tablet, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride36MG · tablet, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride54MG · tablet, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride72MG · tablet, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Jan 11, 2024 | Supplement 16Labeling · Standard review | Approved | None posted |
| Jan 11, 2024 | Supplement 20Labeling · Standard review | Approved | None posted |
| May 21, 2018 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jul 28, 2017 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters